Audit: QRS - Dehydrozingerone for Health & Longevity
Audit conducted on 08/09/2026 05:07 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 84 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | All content traces to the ER: at-a-glance to Conclusion, protocol cells to Therapeutic Protocol, gates to Key Interactions & Contraindications, tiers to Expected Benefits / Potential Risks & Side Effects, table and qualitative list to Monitoring Protocol & Defining Success. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “Unknown in humans”, “no validated human protocol exists”, “No study of dosing time for this compound exists”, “not from any human study” all carried verbatim from the ER. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Speculative tier retained for every benefit and risk; the ER’s ⚠️ Conflicted markers on “Systemic Antioxidant Defense” and “Pro-Oxidant Tissue Stress” are carried through as “(conflicted)”. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications draw only from the ER’s “Populations who should avoid Dehydrozingerone” list; Key Interactions only from the ER’s interaction bullets; no Benefit-Modifying Factors or Risk-Modifying Factors content is surfaced in either gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no PMIDs, citations, expert names, NCT identifiers or brand names; ZinjaBurn/NNB Nutrition were correctly reduced to “Branded ginger extract”. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attribution appears anywhere in the QRS. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s restrained, evidence-first register; phrasing is largely lifted verbatim. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Objective and data-driven throughout; the monitoring panel and protocol cells give the reader actionable structure despite the negative evidence verdict. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Values are presented as market/supplier-derived facts, not as instructions. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Dose cell is explicitly framed as supplier labelling with “no validated human protocol exists”; no imperative clinical instruction appears. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No instances of “recommend”, “advise”, “should”, or comparable guidance verbs in the QRS’s own voice. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the document. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Technical terms are confined to places where they are load-bearing (biomarker names, drug classes); the at-a-glance uses only plain wording. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Thirteen benefits and nine risks compressed to one semicolon-separated line each; ER bullets reduced to one or two sentences. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed: no “you”/”your” anywhere; marker 8 uses “the individual’s own pre-dose baseline”. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Framing assumes a reader weighing a self-directed trial: functional biomarker targets, washout, and pre-surgical windows are all retained. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Retains an eight-marker lab panel, a four-timepoint cadence, and platelet function testing without softening for convenience. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content assumes access to lab testing and continuous glucose monitoring; no general-population simplification. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The at-a-glance states the earliest-stage-of-evidence verdict plainly while the sheet still supplies what a proactive self-experimenter would need to run and monitor a trial. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of “anti-aging” or “antiaging”; the title uses “Health & Longevity”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt. | 🟢 | Formal register throughout (“gastrointestinal irritation”, “elective surgery”, “sulfonylurea”); the plainer at-a-glance wording is mandated by item 7.4. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | Diff against [qrs_template] shows every fixed heading, gate heading and table header byte-identical; the visible tier label “Speculative: “ is unmodified. |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | All 34 template span names present; marker_#_* and qualitative_item_# correctly expanded to 8 and 6 numbered instances respectively (64 spans total, no template span missing). |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | Full-file diff against the template shows changes confined to checklist-addressed spans; website="evidence_review", website="audit", website="full_review", CSS, and the footer disclaimer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section mapped into the QRS is empty; the empty Low tiers are sub-sections governed by the more specific items 12.5 and 13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | “Market-standard dose”, “Best time of day”, “Single versus split dosing” and “Time to effect” all match the ER’s bold labels verbatim. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No invented labels; biomarker names match the ER table’s first column exactly. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | No emoji characters in the file; the ER’s ⚠️ marker is rendered as the plain word “(conflicted)”. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every oversized ER section was condensed rather than carried in full: 13 benefit headings and 9 risk headings each collapsed to a single line, and multi-sentence ER bullets reduced to their key clause. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | Single comment spanning lines 2–14, immediately after <!doctype html> on line 1. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening --- at line 3, closing --- at line 13, preceded only by the permitted comment lead-in. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no metadata value is repeated in <head> or <body>. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, and it contains a colon requiring it. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: dehydrozingerone_2026-0908-0309_Opus_ER.md, matching the ER’s own filename field. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.7.02, matching the version badge in QRS.md. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0908-0454, correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: dehydrozingerone_2026-0908-0309_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified: all nine values trimmed; quoting used only where YAML requires it. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Dehydrozingerone for Health & Longevity - Quick Reference Sheet”; matches ER canonical_topic with & correctly encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Dehydrozingerone for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: “09/08/2026”, correctly derived from qrs_creation_date: 2026-0908-0454. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching the frontmatter. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header holds only the title and the template’s fixed subline; the ER’s “Also known as” list is not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses all four Conclusion paragraphs into the decision-relevant bottom line: preclinical-only evidence base, nothing seen in a person, earliest stage of evidence. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 59 words. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause maps to Conclusion: “ginger-derived half of curcumin”, “permitted flavor material … laboratory curiosity for about forty years”, “comes from cells, flies, mice and rats”, “None of this has been seen in a person”, “earliest stage of evidence”. |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; “less weight gain”, “better sugar handling”, “healthier inflamed organs”, “faster wound closure” are all plain-language renderings. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, or sample size appears. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric effect measure appears; only the qualitative “about forty years” of research history. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items come from that section’s “Populations who should avoid Dehydrozingerone” list. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eight ER avoid-list entries are present, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Eight <li> elements inside the stop_items span (lines 559–569). |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s trailing em-dash clause on the pregnancy item (“— no reproductive or developmental toxicology exists in any species”) is correctly stripped; no other item carries a trailing clause. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “(von Willebrand disease, hemophilia A or B)”, “below 100 × 10⁹/L”, “within 14 days”, “Child-Pugh Class B or C”, “below 30 mL/min/1.73 m²” all preserved; only the definitional eGFR gloss was trimmed, not a qualifier. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s avoid-list bullets use no ranking notation inside parentheses. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
N/A | The section is not left empty; it carries eight items. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not left empty. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items come from that section’s interaction bullets. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Eight of the ER’s ten interaction bullets carried; the two omitted ones (“Insulin and sulfonylureas”, “Ionizing radiation therapy”) are already covered by the Contraindications entries for insulin/sulfonylurea use and active cancer treatment including radiotherapy. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Eight <li> elements inside the caution_items span (lines 577–590). |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every item is reduced to the agent or class name; the ER’s Caution/Monitor labels, mechanisms, consequences and mitigations are all stripped. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Example drug lists preserved for anticoagulants, glucose-lowering supplements and antiplatelet supplements; the NSAID gloss is condensed to “(ibuprofen, naproxen)”, retaining the example drugs. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER’s interaction bullets use no ranking notation inside parentheses. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
N/A | The section is not left empty; it carries eight items. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not left empty. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells derive from Therapeutic Protocol bullets. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, timing and dose-splitting are the three actionable bullets in that section; the remaining bullets are contextual (half-life, competing approaches, polymorphisms, sex, age, baseline state). |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct actionable aspects exist and all three sets are used. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine spans populated; sub-texts track the ER’s supplier-labelling caveat, fat-with-meal rationale and rodent exposure-window reasoning. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | The ER supplies exactly one time-to-effect aspect (Practical Considerations → “Time to effect”), and it is the one used; item 11.3 governs the remaining sets. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | The single set maps to the metabolic benefit, the only benefit the ER gives a timeline for. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | 🟢 | time_2_* and time_3_* spans are emptied and their .pcell wrappers carry style="display: none" (lines 508–529); no placeholder or empty-state text. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | “Time to effect” / “Unknown in humans” / “Rodent metabolic changes emerged over 8–12 weeks of daily feeding.” all match the ER verbatim. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All items come from that section’s Speculative tier. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present (lines 537–549). |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each of the 13 items is reduced to its ER heading alone; every supporting sentence, citation and mechanism is dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No ER parenthetical survives; the only parenthesis, “(conflicted)”, renders the ER’s own “⚠️ Conflicted” heading marker, which item 4.4 bars from being carried as an emoji and item 1.3 bars from being dropped. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | benefits_high, benefits_medium and benefits_low all carry style="display: none" with empty content; the ER’s “No benefit reaches High/Medium” prose is correctly not carried over. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All items come from that section’s Speculative tier. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present (lines 602–613). |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | All nine ER risk headings carried as bare labels; supporting evidence sentences and citations dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No ER parenthetical survives; “(conflicted)” renders the ER’s “⚠️ Conflicted” marker on “Pro-Oxidant Tissue Stress”, required by items 4.4 and 1.3. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | risks_high, risks_medium and risks_low all carry style="display: none" with empty content. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table and cadence both derive from Monitoring Protocol & Defining Success. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All 8 ER table rows present — fasting glucose, HbA1c, fasting insulin, hs-CRP, ALT, eGFR, platelet count, platelet function closure time — with targets and rationales matching verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Lines 735–739 carry all four ER timepoints: baseline within two weeks, week 4, week 12, and after the 4-week washout. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items come from the ER’s “Qualitative markers worth tracking alongside the labs” list. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All 6 present — bruising/bleeding, sleep quality, energy stability, mood and motivation, digestive tolerance, skin — matching the ER text. |
Issues 08/09/2026 05:07
Pass rate 100.00%. No issues found.
Issues 08/09/2026 05:01
- 11.1 / 11.3 — Time-to-effect cells filled with risk-mitigation content: The ER states only one time-to-effect aspect (line 375), but
time_2(“A 12-week cap on total duration per trial”, QRS line 510) andtime_3(“Low starting dose with slow titration”, QRS line 524) are filled from the ERRisk Mitigation Strategiessection (ER lines 315 and 303); both unused sets should have been left empty and made invisible.
Fixes 08/09/2026 05:01
- 11.1 / 11.3 — Unused time-to-effect sets emptied: Cleared the
time_2andtime_3label/value/sub spans and set their.pcellcontainers todisplay: none, removing the risk-mitigation content (“A 12-week cap on total duration per trial” / “12 weeks on, 4 weeks off” and “Low starting dose with slow titration” / “400 mg once daily for 2 weeks”) that had been placed in the Time to Effect row.